Karen Chung serves as our Vice President, Health Economics & Market Access. Dr. Chung has over 25 years in the pharmaceutical and biotechnology industry. Prior to joining Viking, Dr. Chung was Head of Health Economics and Outcomes Research at GRAIL, Inc. and Juno Therapeutics (acquired by Celgene).  Experience also includes both launching products as well as product lifecycle management across therapeutic areas, including Jazz Pharmaceuticals (Vyxeos), Gilead Sciences (antiretrovirals), Amgen (oncology), Baxter BioSciences (plasma-based products), and Bayer Pharmaceuticals (cardiovascular and oncology). Dr. Chung earned her PharmD from the University of Southern California and her Master’s Degree in Health Economics at The University of Arizona.